Monoaminergic and histaminergic strategies and treatments in brain diseases

Frontiers in Neuroscience

Philippe De Deurwaerdère¹  Wieslawa Agnieszka Fogel²  Anna Stasiak²  Nela Pivac³  Dorotea Mück-Šeler³  Dubravka Svob Strac³  Matea Nikolac Perkovic³  Keith Francis Tipton⁴  Irène Bolea⁵  Mercedes Unzeta⁵  Montse Sole⁵  Laura Della Corte⁶  Giuseppe Di Giovanni⁷  Ilse Julia Smolders⁸ 

[1] Centre National de la recherche scientifique (CNRS);Medical University of Lodz;Rudjer Boskovic Institute;Trinity College Dublin;Universitat Autònoma de Barcelona;University of Florence;University of Malta, MT;Vrije Universiteit Brussel;

关键词: Monoamine Oxidase Inhibitors;    Neurodegenerative Diseases;    Stroke;    antidepressant;    Drug Addition;    antiparkinsonian treatments;   

DOI  :  10.3389/fnins.2016.00541

来源: DOAJ

【 摘 要 】

The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson’s disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. Extensive neuropharmacological studies first showed that the primary target of antipsychotics, antidepressants, and anxiolytic drugs were specific components of the monoaminergic systems. Later, some dramatic side effects associated with older medicines were shown to disappear with new chemical compounds targeting the origin of the therapeutic benefit more specifically. The increased knowledge regarding the function and interaction of the monoaminergic systems in the brain resulting from in vivo neurochemical and neurophysiological studies indicated new monoaminergic targets that could achieve the efficacy of the older medicines with fewer side-effects. Yet, this accumulated knowledge regarding monoamines did not produce valuable treatments for diseases where no monoaminergic drug has been shown to be effective. Here, we emphasize the new therapeutic and monoaminergic-based strategies for the treatment of psychiatric diseases. We will consider three main groups of diseases, based on the evidence of monoamines involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes (Parkinson’s disease, addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer’s disease, stroke). In most cases, the clinically available monoaminergic drugs induce widespread modifications of amine tone or excitability through neurobiological networks and exemplify the overlap between therapeutic approaches to psychiatric and neurological conditions. More recent developments that have resulted in improved drug specificity and responses will be discussed in this review.

【 授权许可】

Unknown